Du är här

2016-02-09

Esperite N.V. : GENOMA ENTERS THE SOUTH AFRICAN MARKET WITH INTERCARE

Genoma continues its intercontinental expansion through a partnership with
Intercare, a South African healthcare leader.

Geneva, Switzerland- 9thFebruary 2016

Genoma is now present in the South African market. Thanks to a partnership
with Intercare's firm Salubrity, Tranquility and Serenity are now the main
players within the predictive medicine market in the Rainbow Nation.

With a population of 54 million, and a birth rate of 2.40, South Africa
constitutes a strong market for Genoma's non-invasive prenatal test
"Tranquility" and the breast and ovarian cancer screening test "Serenity".
Thus, the exclusive partnership with a leading provider of integrated
healthcare services in South Africa, guarantees a solid start to Genoma's
offering within the country. Indeed, with its 4 day hospitals, 4 sub-acute
and rehabilitation hospitals, and 16 medical centres, Intercare is a major
player within the South African healthcare system, and so will Genoma.

Genetic counsellors have already been integrated into Intercare's new wellness
company, Salubrity. The goal is to now extend this offering through the
incorporation of Genoma's screening technologies in order to provide a more
inclusive, comprehensive and complete healthcare service. As Intercare CEO Dr
Hendrik Hanekom said "Salubrity means conducive or favourable to health or
well-being [...] this name perfectly encapsulates the principle aim of our
new company, which is to make great health possible".

The partnership with Intercare reinforces Genoma's strategy of becoming a
world leader in genetic diagnostics. The launch of Genoma's products in South
Africa represensents its first milestone into the African continent. Genoma
conciously sought out a well-established, locally-relevant and patent-focused
company in order to ensure appropriate implementation of genetic screening
and testing. "Everyone should be able to have access to the most advanced
technology for
their health because everyone should have access to peace of mind. Genoma is
today bringing both to South Africa, and will use this as the basis for
further expansion later on.
" said CEO Frederic Amar.

About ESPERITE

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading
international company in regenerative and predictive medicine established in
2000.

To learn more about ESPERITE Group, or to book an interview with CEO Frederic
Amar: +31 575 548 998 - ir@esperite.com or visit the websites
atwww.esperite.com andwww.genoma.com.

GENOMA ENTERS THE SOUTH AFRICAN MARKET WITH INTERCARE
http://hugin.info/143308/R/1984576/727605.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via Globenewswire

HUG#1984576

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.